SOBI

News

Sobi pays $1.5bn for Arthrosi to grow in gout

Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage testing for gout.

News

UK haemophilia A patients get once-weekly treatment option

A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

News

$refractory chronic gout$

Sobi starts rolling FDA filing for chronic gout drug

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to cu

News

Sobi gets EU okay for long-acting haemophilia A drug

The European Commission has approved Sobi’s long-acting factor VIII replacement therapy Altuvoct for the treatment of haemophilia A in the EU, with a broad label that spans all ages and any

News

Apellis drops ALS drug, in another blow to patients

The litany of failed experimental therapies for amyotrophic lateral sclerosis (ALS) added another verse today, after Apellis Pharma gave up on Sobi-partnered candidate peg

Sobi pays $1.5bn for Arthrosi to grow in gout

UK haemophilia A patients get once-weekly treatment option

11 blockbuster drugs to look out for in 2025

Sobi starts rolling FDA filing for chronic gout drug

Sobi gets EU okay for long-acting haemophilia A drug

Apellis drops ALS drug, in another blow to patients

On the future of AI in life sciences, with women at the helm

How to meet your physicians where they are online

SOBI

Editor's Picks